Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir.

The Journal of antimicrobial chemotherapy - 1 May 2017

Todt Daniel, Schlevogt Bernhard, Deterding Katja, Grundhoff Adam, Manns Michael P, Wedemeyer Heiner, Fischer Nicole, Cornberg Markus, Steinmann Eike

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Naphthylamine
Share to Anilides
Share to Cyclopropanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Retreatment

Share to Ritonavir

Share to Uracil

Source

Identifiers

PMID: 28100444
DOI: 10.1093/jac/dkw572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir.PMID 28100444Read ↗

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.Semantic proximity Read ↗

Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.Semantic proximity Read ↗

[A real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C].Semantic proximity Read ↗

Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Semantic proximity Read ↗

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.Semantic proximity Read ↗

Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir ± Ribavirin following protease inhibitors failure - A Prospective Multi-Centre TrialSemantic proximity Read ↗

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.Semantic proximity Read ↗

Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.Semantic proximity Read ↗

Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.Semantic proximity Read ↗

Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.Semantic proximity Read ↗

[Real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in China].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.